Cleavage of proalbumin peptides by furin reveals unexpected restrictions at the P2 and P′1 sites  by Brennan, Stephen O. & Nakayam, Kazuhisa
FEBS Letters 347 (1994) 80-84 
FEBS 14125 
Cleavage of proalbumin peptides by furin reveals unexpected restrictions 
at the P2 and P'I sites 
Stephen O. Brennan a'*, Kazuhisa Nakayama b
aMolecular Pathology Laboratory, Clinical Biochemistry Christchurch Hospital, Christchurch, New Zealand 
blnstitute of Biological Sciences, University of Tsukuba, Tsukuba, lbaraki 305, Japan 
Received 7 April 1994; revised version received 2 May 1994 
Almtract 
Proalbumin is the principal substrate of the in situ hepatic onvertase. Here we investigated the specificity of furin using synthetic peptides based 
on the N-terminal sequeaee of human proalbumin. The propeptide was rapidly cleaved from the normal ( ( -6)RGVFRR(-  1)DAHKSEAVW(+ 9)) 
peptide but as expected, there was no cleavage of the proalbumin Lille analogue with a -2  His (-2H). Surprisingly, the effect of this substitution 
could not be corrected by introducing a -4  Arg ( -4R-2H) .  In contrast, the peptide -4R-2A was an excellent substrate being cleaved five times 
faster than normal, indicaabting that His is not allowed as an P2 residue. Replacement of the -4  Val by Glu supported the expected importance of 
a positive charge at P4 as the cleavage rate dropped to 10% of normal after this substitution. The -6  Arg makes a small contribution to cleavage, 
its replacement by Aia decreased the cleavage rate to 60% of normal. The Lys-Arg propeptide was almost as good a substrate as the normal Arg-Arg 
peptide, but the introduction of a Lys at P'1 totally abolished processing. The exclusion of P't positive charges would be an important requirement 
for preventing aberrant cleavage in the middle of tetrabasic sequences. 
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1. Introduction 
Since the discovery of the first mammalian KEX2-like 
protease in hepatic secretory vesicles [1] a series ofcDNA 
homologs (furin PC2, PCI/3, PC4, PC6 and PACE4) of 
this yeast convertase has now been identified in different 
mammalian tissues [2-10]. Members of this emerging 
family of Ca z+ -dependent serine proteases vary in their 
site of expression and in the basic sequence that they 
recognise. 
Although furin mRNA is expressed ubiquitously, it
reaches particularly high levels in the liver, making it a 
likely candidate as an endogenous hepatic convertase. 
Although some 23 different proproteins are constitu- 
tively cleaved before export from the liver, quantitatively 
the amount of proalbumin processed far exceeds that of 
all other proproteins combined. 
We have recently shown that a purified recombinant 
form of furin correctly cleaved the propeptide (Arg-Gly- 
Val-Phe-Arg-Arg) from human proalbumin but failed to 
cleave unprocessed natural variants with mutation of 
-2Arg---~His, - 1Arg---~Gln, + I Asp--~Val and -2Arg---) 
Cys, giving this protease the correct credentials as an in 
situ convertase [11]. 
In order to further define the substrate requirements 
of furin and to capitalise on the insights already gained 
from the natural variants, we examined its ability to 
*Corresponding author. Fax: (64) (3) 364-0750. 
cleave a series of synthetic peptides based on the N- 
terminal of human proalbumin. 
2. Materials and methods 
The establishment of the CHO cell line, CHO/A704, expressing the 
A704 mutant of mouse furin has been previously described, as has the 
purification of this C-terminally truncated form of the enzyme [12]. The 
major 81183 kDa doublet form of the protease was used in this investi- 
gation and it had a specific activity of 178 U/rag where 1 U is defined 
as the amount which hydrolyses 1 nmol Boc-Arg-Val-Arg-Arg-MCA 
per rain at pH 7.0 and 37°C [12]. The purified furin was stored at a 
concentration f 13.3 U/mi at - 100°C in 10 mM MES, 1 mM CaCIe 
containing 5 mg/ml ovalbumin~ until required. 
Synthetic peptide substrates were based on the N-terminal sequence 
of human proalbumin and were obtained from Chiron Mimotopes, 
Vic., Australia. All peptides were 15 residues long and had blocked 
N-(acetyl) and C- (amide) terminals. Trp rather than the normal His 
was incorporated atposition + 9 to facilitate the rapid identification of
the N- and C-terminal cleavage fragments. The purity and sequence 
fidelity of the peptides were determined/verified by the manufacturer 
using ion spray/triple quadrapole mass spectrometry. 
The reaction mixture for each assay contained 1 nmol of proalbumin 
peptide in 2.5/1150 mM MES, 1 mM CaC12 pH 5.5 containing 1 mg/ml 
globin. To this was added 0.35 ~tl (4.5 mU) of furin and the solution 
incubated at 30°C for specified times between 0.5 and 8 h. The reaction 
was stopped by the addition of 50/11 of buffer A (below) and after 
microfuging 40 ~1 was injected onto a 3/~ Nova Pac C-18 column and 
the extent of hydrolysis determined by HPLC. The solvent system 
consisted of: solvent A, 49 mM phosphate buffer, pH 2.9; B, equal 
mixture of solvent A and acetonitrile [13]. The flow rate was 1 ml/min 
and the gradient went from 18 to 46% B over 14 rain. The absorbance 
was monitored at both 215 and 254 urn. In order to negate the effects 
of any slight variation in injection volume between runs the reaction 
rate was calculated as percentage conversion/rain. This was expressed 
as peak height of the C-terminal product divided by height of the 
C-terminal product + height of the parent peptide peak. 
Amino acid analysis of isolated cleavage products was performed 
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using the PITC derivatisation procedure, and sequence analysis was 
performed on an Applied Biosystems 471A instrument. 
3. Results 
Table 1 shows the sequences ofthe variant proalbumin 
peptides that were used in this study and their retention 
times in the HPLC assay system. The peptides were 
greater than 90% pure as judged by HPLC (not shown) 
and this was consistent with the manufacturer's a sess- 
ment using ion spray mass spectrometry. The normal 
sequence has been designated peptide A and the number- 
ing system of serum albumin has been retained, with 
residues - 1 to - 6 representing the propeptide and 1 to 
9 the mature N-terminal sequence. 
Incubation of the normal peptide A with furin (Fig. 1) 
resulted in its progressive hydrolysis and the concomi- 
tant appearance of two more polar peaks, the second of 
which contained the Trp residue, as indicated by the 254 
nm absorbance trace (not shown). The identity of both 
products was confirmed by composition/sequence analy- 
sis as RGVFRR and DAHKSEVAW, respectively, and 
the hydrolysis rate was 0.75 nmol/min/U enzyme. 
As neither furin nor the in situ hepatic convertase 
cleave the natural circulating variant proalbumin Lille 
(-2Arg~His), it was not surprising to find that the 
proalbumin peptide (-2H) with the corresponding sub- 
stitution was not hydrolysed even after 8 h incubation 
(Fig. 2). 
We reasoned, however, that because of the known 
preference of furin for paired arginines in either a -2 -1  
or -4 -1  configuration, the introduction of a -4R  in the 
Lille peptide analogue would convert it to a substrate 
that might be cleaved faster than the normal peptide. 
This was not the case since, despite its apparently ideal 
-6 -4 -1  triplet Arg sequence there was no cleavage of 
the -4R-2H peptide ven after 8 h (Fig. 2). This sug- 
Table 1 
Sequences of proalbumin peptides 
Cleavage Relative Retention 
rate + rate # time (min) 
-5 -1 1 5 
A ~-R GV F R R D A HK S E V A W-NH~ 0.75 100 12 
-2H H 0.00 0 12 
-4R-2H R H 0.00 0 8.5 
-4E E 0.06 8 8.5 
-2K K 0.51 72 12 
-6A A 0.17 22 15 
+IK K 0.00 0 II 
-4R-2A R A 3.55 474 10.5 
Proalbumin R GV F R R D A H K S E V A H 
+ nmol/min/U enzyme. 
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Fig. 1. Reverse-phase HPLC profile showing furin catalysed cleavage 
of proalbumin peptide A (normal). 1 nmol samples of peptide were 
analyzed after 0, 2, 4 and 8 h incubation with furin (0.25 fM); 3g C-18 
column, detection at 215 nm; other details in text. 
gests that furin's sequence r quirements disallow a P2 His 
under any circumstances. 
To further explore the requirement for substrates with 
a positive residue in the P4 position, we examined the 
hydrolysis of a peptide (-4E) where the natural Val was 
replaced by a negatively charged Glu residue. In this 
case, the cleavage rate was substantially reduced with a 
decrease to 8% of the normal peptide (Figs. 2 and 3). 
Note that in this case only the C-terminal product is seen 
as the increased polarity of the propeptide causes it to 
emerge in the injection peak. 
The positive contribution to the cleavage rate of a 
-4Arg residue was further established by examining 
the hydrolysis of peptide - 4R-  2A. This contained a -4, 
instead of a -2  Arg residue. Not only did cleavage take 
place, but the rate was 5-times faster than that of the 
normal peptide (Figs. 2 and 3). This result, taken to- 
gether with the complete failure to cleave the corre- 
sponding -4R-2H peptide, confirms that histidine must 
be excluded for the -2  position. 
Peptide -2K  was investigated to establish if a Lys- 
Arg sequence was as effective as an Arg-Arg as a permit- 
ted processing site. Good cleavage was observed (Fig. 2) 
with the rate (0.51 nmol/min/U enzyme) only sightly less 
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Fig. 2. Cleavage of variant proalbumin peptides by furin. Top left panel: normal peptide (RGVFRRDAHKSEVAW); subsequent panels show 
variants with the designated substitutions. The data showja is for a 4 h incubation except in the case of - 4R-  2A where the 1 h incubation is shown. 
P, parent peptide; N, N-terminal fragment; C, C-terminal fragment. HPLC conditions as described in section 2. 
than that (0.75 umol/min/U enzyme) for the normal Arg- 
Arg peptide. 
It has been suggested that the lack of a -4Arg in the 
sequence of human proalbumin might be partially offset 
by the presence of Arg in the - 6 position. We found that 
the -6Arg does make a significant contribution to cleav- 
age since its replacement by Ala in peptide -6A  resulted 
in a four-fold reduction in the hydrolysis rate of the 
peptide (Figs. 2 and 3). 
There has been little examination of the contribution of 
the P'I site to peptide bond cleavage. This is partly be- 
cause there are no suitable chromogenic/fluorogenic sub- 
strates available, since the reporting roup itself occupies 
the lYl site, and because comparison of the sequence in 
this area in a series of proproteins (Table 2) does not 
reveal any obvious trend that might be exploited by site- 
directed mutagenesis. If furin is the in situ hepatic on- 
vertase, however, then it must be able to cleave after tri- 
and tetrabasic sequences (e.g. RRKR or RRRR) without 
cleavage after the first dibasic pair (RR). This could be 
achieved if the enzyme's pecificity excluded positive 
charges in the P'I position. To test this possibility, we 
examined the cleavage of peptide + 1K where the P'I Asp 
was replaced by Lys, and confirmed that this change 
totally blocked processing at the Arg- Arg site 
4. Discussion 
The findings here provide new insights into the pri- 
mary sequences that are recognised by furin, and 
strengthen furin's suggested role as an in situ hepatic 
convertase [11]. 
The rat hepatic converting enzyme was previously 
shown to have a preference for chicken proalbumin with 
a processing sequence of RFAR over human proalbumin 
(VFRR). It was suggested that the hepatic vesicle activity 
was principally directed towards an RXYR or XYRR 
sequence with a 5- to 10-fold preference for the former 
[14]. We find that purified furin has a similar specificity, 
cleaving the RFAR proalbumin peptide five times faster 
than the normal VFRR peptide. 
The finding that furin cleaved the KR site of the -2K 
peptide almost as efficiently as it cleaved the RR peptide 
was unexpected since the hepatic vesicle activity fails to 
cleave at the PQKR site of proinsulin [14]. However, if 
furin is 'the' hepatic onvertase, it would be necessary for 
it to be capable of cleaving at some simple KR sites since 
the processing of proprotein C involves cleavage at both 
an IRKR and a HLKR site (Table 2). Co-expression 
experiments are also consistent with this having shown 
that furin can cleave at some, e.g. mutant, pro Von Wil- 
lebrand factor (ASKR) [10], but not all, e.g. prorenin 
(FTKR) [15], KR sites. Elucidating the precise features 
that make some KR sites favourable will need further 
investigation. 
That these propeptide analogues correctly mimic their 
natural equivalents i well established by the processing 
of the normal peptide and lack of processing of the pro- 
albumin Lille analogue with the -2H. We have previ- 
ously shown that neither the hepatic activity nor purified 
furin cleave proalbumin Lille (-2Arg ~His) [11], and 
Matsuo [16] has demonstrated that a synthetic Lille pep- 
tide is not cleaved by hepatic vesicle extracts. 
A novel restriction to furin's specificity was discovered 
in its failure to cleave the -4R-2H peptide. The positive 
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effects of the highly favoured -4 - I  diarginyl sequence 
that was observed for the RFAR sequence were totally 
abolished if the - 2 residue was a His. This is particularly 
surprising since at the pH used (5.5) the peptide would 
have positive centers at the -2  as well as at the -4  and 
- 1 sites. This finding does, however, strengthen furin's 
role as an in vivo hepatic convertase since of the 23 
different proprotein sites that are cleaved uring the ex- 
port from the mammalian liver, none has a P~ His (Table 
2). Indeed, when mammalian species variation is taken 
into account, this number increases to 47 out of 47 sites 
that lack a -2  His. 
The 78% decrease in cleavage rate observed when the 
- 6R of proalbumin was replaced by Ala, points to the 
enhancing effect of this residue on processing at XYRR 
sites, and is reflected by the presence of a -6R  residue 
in other hepatic substrates with a simple XYRR site such 
as the protein C junction (Table 2). The in situ cleavage 
at this site is still, however, suboptimal since 10-20% of 
circulating protein C is in the single chain form [17]. 
Many hepatic substrates have consecutive tri- or tetra- 
basic sequences, e.g. RRRR (Table 2) and since furin is 
capable of cleavage after RR sites, a potential problem 
arises where there might be aberrant cleavage after the 
Table 2 
Processing site sequences of human liver proproteins 
Plasma proteins P6 P5 P4 P3 I)2 P1 P'] P'2 P'3 
Proalbumin R G V F R R D A H 
Proalbuminc L Q R F A R D A E 
Pro-apoA2 - A L V R R Q A K 
Pro- lgTi l  I P R V R R A V L 
Pro-lgTi2 N R R Y Q R S L P 
Coagulation factors 
Fibrinogeng-chain K S R P V R G I H 
Prothromhin L Q R V R R A N T 
ProfactorIX L N R P K R Y N S 
ProfactorX L A R V T R A N S 
FactorXh/ lchain L E R R K R S V A 
ProfactorXII L H R R R R A N A 
ProproteinC L R I R K R A N S 
ProteinCh/lchain R S H L K R D T E 
ProproteinS L V R K R R A N S 
ProproteinZ L V R W K R A G S 
Receptors 
Insulinproreceptor P S R K R R S L G 
IGFproreceptor P E R K R R D V M 
Pro-LDLRRP S N R H R R Q I D 
HGFreceptor E K R K K R S T K 
Complement system 
C3~/fljunction A A R R R R S V Q 
C4cdfljunction T T R K K R N V N 
C4ct/7,junction R N R R R R E A P 
C5~fljunction I L R P R R T L Q 
Convertases 
Profurin K R R T K R D V Y 
Pro-lg Ti = prointer g-trypsin inhibitor, IGF = insulin-like growth fac- 
tor, Pro-LDL RRP = pro LDL receptor-related protein, Chicken pro- 
albumin (c) is included for comparison. 
100 q ~ -4R-2A 
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Fig. 3. Cleavage of designated synthetic proalbumin peptides by furin 
as a function of time. 
first paired sequence. This could be avoided if the pro- 
tease had a specificity restriction to exclude P'I basic 
residues. Furin appears to have just this specificity; there 
was no cleavage of the + 1Lys peptide. This finding adds 
to the restrictions imposed on this site that exclude large 
alkyl sidechains (Val-Leu-Ile) that was first highlighted 
by the discovery of the unprocessed variant proalbumin 
Blenheim (+ 1Asp-->Val) [18] and expanded by site-di- 
rected mutagenesis of proalbumin [19]. 
The role that the furin homolog PACE4 may play in 
the liver is presently unclear but recent co-expression 
experiments have shown it to be proteolytically active 
and somewhat different o furin in its cleavage of mu- 
tated pro Von Willebrand factor (which is not produced 
in hepatocytes but endothelial cells). PACE4's lack of 
inhibition by g:antitrypsin Pittsburgh [20], however, 
makes it substantially different from furin and the in situ 
enzyme. The findings here, on the other hand, show that 
furin has a similar specificity to that expected of the in 
situ convertase. This, together with its inhibition by an- 
titrypsin Pittsburgh, indicate that it could play a major 
role in liver processing. The substrate specificity of 
PACE4 should now be compared to the in vivo sequence 
and furin in order to assess its possible contribution to 
liver processing. 
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